12 Best Growth Stocks Trading in Oversold Territory
On June 11, Emily Roland, the Co-Chief Investment Strategist at Manulife John Hancock Investment Management, joined 'Squawk Box' on CNBC to discuss where investors can find opportunity right now.
Roivant Sciences Ltd. (ROIV)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | QVT Financial Daniel Gold | 25,161,237 | $696,966,265 | -5% | 51.04% |
| 2. | Adage Capital Management Phill Gross And Robert Atchinson | 12,794,097 | $354,396,487 | +20% | 0.55% |
| 3. | Farallon Capital Thomas Steyer | 9,675,000 | $267,997,500 | +26049% | 1.53% |
| 4. | Two Seas Capital Sina Toussi | 9,328,291 | $258,393,661 | -5% | 3.61% |
| 5. | Perceptive Advisors Joseph Edelman | 8,285,461 | $229,507,270 | +4% | 4.48% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.07 | 3,315 | $49,957.05 | 17,287,081 | 2025-09-18 | Filing | |
| $5.00 | 4,000,000 | $20,000,000.00 | 102,849,443 | 2022-11-10 | Filing | |
| $3.91 | 8,600 | $33,635.46 | 98,849,443 | 2022-04-25 | Filing | |
| $3.83 | 31,685 | $121,318.70 | 98,840,843 | 2022-04-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $34.90 | 10,000 | $349,000.00 | 42,963 | 2026-06-30 | Filing | |
| $34.71 | 2,748 | $95,383.08 | 16,474 | 2026-06-29 | Filing | |
| $34.32 | 15,002 | $514,868.64 | 19,222 | 2026-06-29 | Filing | |
| $35.45 | 200,000 | $7,090,000.00 | 1,748,403 | 2026-06-30 | Filing | |
| $35.28 | 12,380 | $436,766.40 | 13,689,166 | 2026-06-30 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,362,952 | $295,964,871 | 0.37% | |
| 2. | 90,228 | $3,193,169 | 0.54% | |
| 3. | 32,970 | $1,166,808 | 0.62% | |
| 4. | 14,637 | $518,003 | 0.02% | |
| 5. | 3,995 | $141,383 | 0.01% |
News See All
Guggenheim Remains Bullish on Roivant Sciences Ltd. (ROIV)
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best healthcare stocks to buy with highest upside potential. Guggenheim lifted the price target on Roivant Sciences Ltd.
10 Best Healthcare Stocks to Buy with Highest Upside Potential
On June 1, Tom Lee, Fundstrat managing partner and head of research, and Fundstrat Capital CIO, appeared on CNBC’s ‘Squawk Box’ to talk about the latest market trends, the market outlook, and more...
15 High Growth Stocks to Buy and Hold for the Next Decade
High-growth stocks are getting more attention as investors look beyond the first wave of AI winners and try to identify companies that can still compound earnings over a longer period.
Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. Welcome to the Roivant Fourth Quarter 2025 Earnings Call.
Roivant (ROIV) Climbs 15% on Swing to Profits
Roivant Sciences grew its share prices by 14.89 percent on Wednesday to close at $32.41 apiece, as investors took heart from its swing to profitability in the fourth quarter of fiscal year 2026, while...
10 Stocks With Insane Returns Right Now
POET Technologies snapped a three-day losing streak on Wednesday, climbing 13.08 percent to close at $14.78 apiece, after announcing an aggressive plan to expand its wafer manufacturing capabilities by...
Here’s Why Roivant Sciences Ltd (ROIV) Rallied in Q1
Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here.
10 Best Medical Stocks to Buy Under $30
On April 28, Reuters reported that the US Food and Drug Administration has introduced a new pilot program that would allow the agency to monitor clinical trial data in real time.
15 Under-the-Radar Picks from David Einhorn That Are Quietly Dominating 2026
David Einhorn, the founder and president of Greenlight Capital, is widely regarded as one of the most intellectually rigorous and disciplined value investors of his generation.
Hedge Fund Resource Center